8-K: Neuraxis Secures $3.3M At-The-Market Equity Offering

Neuraxis, Inc. has entered into an At The Market Offering Agreement to sell up to $3.3 million of common stock, providing flexible access to capital.

Summary

• Neuraxis, Inc. (NRXS) entered into an At The Market (ATM) Offering Agreement with Craig-Hallum Capital Group LLC to act as its sales agent.
• The agreement allows for the sale of up to $3,300,000 of the company's $0.001 par value common stock from time to time, at its sole discretion.
• Sales will be conducted as an 'at the market' offering, as defined by Rule 415(a)(4) under the Securities Act of 1933, and may include privately negotiated transactions with prior company approval.
• Craig-Hallum Capital Group LLC will receive a commission of 3% of the gross sales proceeds from any common stock sold through the agreement.
• The company will reimburse the sales agent for legal counsel fees up to $50,000 initially, and up to $5,000 for each subsequent due diligence update session.
• The offering is made under an effective Registration Statement on Form S-3 (File No. 333-283798), which was declared effective on February 11, 2025, with a prospectus supplement filed on August 29, 2025.

Sentiment

Score: 6

Explanation: The filing indicates a proactive step to secure flexible funding, which is positive for operational stability and future growth initiatives. However, the potential for shareholder dilution and the costs associated with the offering introduce a moderate negative aspect, balancing the overall sentiment to slightly positive.

Positives

• Provides Neuraxis with a flexible and efficient mechanism to raise up to $3.3 million in capital as needed, without the fixed costs of a traditional underwritten offering.
• Allows the company to access public markets opportunistically, potentially reducing market timing risks.
• Offers discretion to the company regarding the timing, price, and size of share sales, enabling strategic fundraising.

Negatives

• Potential for dilution of existing shareholders as new common stock is issued and sold into the market.
• Costs associated with the offering include a 3% commission on gross sales proceeds to the sales agent, plus legal counsel reimbursements up to $50,000 initially and $5,000 per due diligence update.
• The actual amount of capital raised is uncertain and dependent on market conditions and the company's discretion.

Risks

• Shareholder Dilution: The issuance and sale of new common stock will dilute the ownership percentage of existing shareholders.
• Market Price Volatility: The sale of shares 'at the market' means the price will fluctuate with market conditions, potentially impacting the average sale price and total proceeds.
• Execution Risk: There is no assurance that the sales agent will be successful in selling the maximum amount of shares, or any shares, for reasons other than a failure to use commercially reasonable efforts.
• Regulatory Compliance: Ongoing compliance with SEC and Trading Market rules and regulations is required, with potential for stop orders or suspensions if not met.

Future Outlook

The company may offer and sell shares of its common stock from time to time at its sole discretion, utilizing the At The Market Offering Agreement to raise capital as market conditions and company needs dictate. The net proceeds from any sales will be applied in the manner set forth in the Prospectus.

Management Comments

• Brian Carrico, President and Chief Executive Officer, signed the report on behalf of Neuraxis, Inc.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool for publicly traded companies, particularly those seeking to raise capital opportunistically without the fixed costs and market timing risks associated with traditional underwritten offerings. This approach allows companies to tap into market liquidity as needed, often favored by smaller-cap companies or those with fluctuating capital requirements.

Comparison to Industry Standards

• ATM offerings are a standard capital-raising mechanism in the financial industry, widely adopted by companies across various sectors.
• A 3% commission rate for the sales agent is within the typical range for such facilities.
• The use of a Form S-3 shelf registration statement is standard practice for eligible companies seeking efficient access to capital markets.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new common stock is issued.
• Company: Enhanced financial flexibility and access to capital for general corporate purposes, potentially supporting growth or operational needs.

Next Steps

• The company may, at its sole discretion, instruct the sales agent to sell shares of common stock from time to time.
• Ongoing due diligence sessions will be conducted, with associated legal counsel reimbursements.
• The company will disclose the number of shares sold, net proceeds, and compensation in its Annual and Quarterly Reports.

Key Dates

Recommendation

This filing details a standard At The Market (ATM) offering, which provides Neuraxis with a flexible mechanism to raise capital. While access to capital is generally positive for a company's operational runway and strategic initiatives, the potential for shareholder dilution is a key consideration. The offering itself does not provide new operational or financial performance data that would fundamentally alter the investment thesis. Investors should monitor the actual utilization of the ATM facility and the company's subsequent financial performance and strategic execution rather than reacting solely to the establishment of this financing vehicle.

Keywords

Neuraxis, NRXS, ATM Offering, Equity Offering, Capital Raise, Common Stock, Dilution, Craig-Hallum Capital Group, SEC Filing, Form S-3, Financial Reporting, Corporate Finance